AstraZeneca Stock Symbol AZN Investment Overview

AstraZeneca is a multinational biopharmaceutical company with a rich history dating back to 1999, when it was formed by the merger of two companies: Astra AB and Zeneca Group.

The company's stock symbol is AZN, which is listed on the London Stock Exchange and the New York Stock Exchange.

AstraZeneca is known for its diverse portfolio of prescription medicines, including those for cardiovascular, gastrointestinal, neuroscience, oncology, and respiratory conditions.

One of its most notable products is the COVID-19 vaccine, AZD1222, which has been widely used around the world to combat the pandemic.

A different take: Ticker Symbol and Stock Exchange for Given Company Neximmune Inc

AstraZeneca PLC (AZN) has been recognized by multiple analysts as a top pick in the pharmaceutical sector.

The company has shown impressive financial performance with a reported 19% increase in earnings and revenues.

AstraZeneca is actively developing a robust pipeline of nine new drugs, promising significant future revenues estimated at $5 billion.

Its focus on oncology and recent successes in trial data further bolster the outlook for AstraZeneca's stock, positioning it as a long-term investment opportunity.

See what others are reading: Stock Symbol B

Experts express bullish sentiments about the company's trajectory, supported by ongoing research and development advancements.

AstraZeneca's valuation metrics are attractive, with a significant return on equity (ROE) of up to 30% and trading at various price-to-earnings ratios ranging from 14x to 32x.

Here's a summary of AstraZeneca's share price performance over the past year:

AstraZeneca's stock is trading at around 14x earnings, which is considered under-valued.

This makes it an excellent time to purchase shares for the long-term shareholder.

AstraZeneca's stock symbol is AZN, and its market capitalization is over $200 billion, making it one of the largest pharmaceutical companies in the world.

The company's revenue has consistently grown over the years, with a compound annual growth rate (CAGR) of 10% from 2015 to 2020.

AstraZeneca's strong financial performance is driven by its diverse portfolio of products, including cancer treatments, cardiovascular medications, and respiratory therapies.

In the world of investment analysis, valuation is a crucial step in determining the worth of a company. It helps investors make informed decisions about whether to buy, hold, or sell a stock.

Let's take a look at some key valuation metrics for three companies: AZN, LLY, and MRK.

Price/Earnings (Normalized) is a metric that shows how much investors are willing to pay for each dollar of earnings. For AZN, this ratio is 15.64, indicating that investors are paying a relatively high price for each dollar of earnings.

LLY has a significantly higher Price/Earnings (Normalized) ratio of 54.81, suggesting that investors are willing to pay a premium for this company's earnings.

MRK, on the other hand, has a much lower Price/Earnings (Normalized) ratio of 11.95, indicating that investors are paying a relatively low price for each dollar of earnings.

Here's a summary of the Price/Earnings (Normalized) ratios for these three companies:

These metrics can give us a better understanding of the relative value of each company, but it's essential to consider other factors as well.

When analyzing the profitability of a company, there are several key metrics to consider.

Return on Assets (ROA) is a crucial metric that shows how efficiently a company is using its assets to generate revenue. According to the data, AZN has a normalized ROA of 12.32%, while LLY has a significantly higher ROA of 16.58%.

A higher Return on Equity (ROE) indicates that a company is generating more profit from its equity. LLY has an impressive normalized ROE of 89.56%, which is substantially higher than AZN's 32.21% and MRK's 36.52%.

A Return on Invested Capital (ROIC) of 19.39% for AZN suggests that the company is generating a decent return on the capital invested in it. On the other hand, LLY's normalized ROIC of 29.02% indicates a higher return on investment.

Here's a comparison of the normalized profitability metrics for AZN, LLY, and MRK:

MRK's normalized ROIC of 20.57% is slightly higher than AZN's, indicating a relatively efficient use of capital.

AstraZeneca has a level 2 ADR programme listed on Nasdaq under the symbol AZN. The programme was established in 1999 after Astra and Zeneca merged.

The ADR ratio is 1:2, meaning each ordinary share is represented by 2 ADRs.

J.P. Morgan Chase Bank, N.A. is the depositary bank for the programme.